Clinical trial NCT02533505 - References

Chronic Obstructive Pulmonary Disease (COPD) — Phase IV O2 Consumption Study in COPD Patients.

Citation(s)

•   Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S
  Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005 Mar;127(3):809-17.
•   Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR
  Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005 Mar 15;171(6):591-7.
•   Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, Centanni S
  Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J. 2003 Jan;21(1):86-94.
•   Díaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emili J, Lisboa C
  Breathing pattern and gas exchange at peak exercise in COPD patients with and without tidal flow limitation at rest. Eur Respir J. 2001 Jun;17(6):1120-7.
•   Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force
  Standardisat
•   O'Donnell DE, D'Arsigny C, Fitzpatrick M, Webb KA
  Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. Am J Respir Crit Care Med. 2002 Sep 1;166(5):663-8.
•   O'Donnell DE, Lam M, Webb KA
  Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1557-65.
•   O'Donnell DE, Lam M, Webb KA
  Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Aug;160(2):542-9.
•   O'Donnell DE, Revill SM, Webb KA
  Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Sep 1;164(5):770-7.
•   Seibold H, Roth U, Lippert R, Kohler J, Wieshammer S, Henze E, Stauch M
  Left heart function in chronic obstructive lung disease. Klin Wochenschr. 1986 May 2;64(9):433-41.
•   Sexton WL, Poole DC
  Effects of emphysema on diaphragm blood flow during exercise. J Appl Physiol (1985). 1998 Mar;84(3):971-9.
•   Sinderby C, Spahija J, Beck J, Kaminski D, Yan S, Comtois N, Sliwinski P
  Diaphragm activation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Jun;163(7):1637-41.
•   Stewart RI, Lewis CM
  Cardiac output during exercise in patients with COPD. Chest. 1986 Feb;89(2):199-205.
•   Synn A, Pinto-Plata V, Perham C, Celli B, Divo M
  Improvement in cost of breathing after use of budesonide/formoterol in COPD patients with static hyperinflation. Presented at The American Thoracic Society International Conference, May 16-21, 2014.
•   Vassaux C, Torre-Bouscoulet L, Zeineldine S, Cortopassi F, Paz-Díaz H, Celli BR, Pinto-Plata VM
  Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J. 2008 Nov;32(5):1275-82. doi: 10.1183/09031936.00151707
•   Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G
  Standardisation of th
•   Yan S, Kaminski D, Sliwinski P
  Reliability of inspiratory capacity for estimating end-expiratory lung volume changes during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997 Jul;156(1):55-9.

A Phase 4, Randomized, Double-blind, Multicenter, Placebo-Controlled Two Way Cross-Over Study to Evaluate Changes in Oxygen Consumption and Cardiac Function in COPD Patients With Resting Hyperinflation After Administration of Symbicort pMDI 160/4.5 μg.

Details for clinical trial NCT02533505